Загрузка...
Nivolumab in Combination With Platinum‐Based Doublet Chemotherapy for First-Line Treatment of Advanced Non–Small-Cell Lung Cancer
PURPOSE: Nivolumab, a fully human immunoglobulin G4 programmed death-1 immune checkpoint inhibitor antibody, has demonstrated improved survival in previously treated patients with advanced non–small-cell lung cancer (NSCLC). CheckMate 012, a phase I, multicohort study, was conducted to explore the s...
Сохранить в:
| Опубликовано в: : | J Clin Oncol |
|---|---|
| Главные авторы: | , , , , , , , , , , , , , , , |
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
American Society of Clinical Oncology
2016
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5569693/ https://ncbi.nlm.nih.gov/pubmed/27354481 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2016.66.9861 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|